# Entecavir and Pegasys Sequential Therapy Versus Pegasys for HBeAg Negative Chronic Hepatitis B

> **NCT00917761** · PHASE4 · UNKNOWN · sponsor: **National Taiwan University Hospital** · enrollment: 300 (estimated)

## Conditions studied

- Hepatitis B, Chronic

## Interventions

- **DRUG:** Entecavir and peginterferon (Pegasys) (52 weeks)
- **DRUG:** Peginterferon (Pegasys) (96 weeks)
- **DRUG:** Peginterferon (Pegasys) (48 weeks)

## Key facts

- **NCT ID:** NCT00917761
- **Lead sponsor:** National Taiwan University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2007-02
- **Primary completion:** 2013-12
- **Final completion:** 2013-12
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2012-12-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00917761

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00917761, "Entecavir and Pegasys Sequential Therapy Versus Pegasys for HBeAg Negative Chronic Hepatitis B". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT00917761. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*